Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.
